GTGodwin Tusabe

Godwin Tusabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Godwin Tusabe has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Harnessing Genomics for Public Health: Use-Case Insights from Uganda

    by Aloysious Ssemaganda, Alisen Ayitewala, Stephen Kanyerezi, Hellen Rosette Oundo, Julius Seruyange, Wilson Tenywa, Godwin Tusabe, Stacy Were, Moses Murungi, Ivan Sserwadda, et al.

    Genomic technologies are transforming infectious disease surveillance and control, particularly in resource-limited settings such as Uganda. This review examines ongoing efforts by the Department of National Health Laboratory and Diagnostic Services - Central Public Health Laboratories (NHLDS-CPHL) to integrate genomics into public health strategies. We highlight key advancements, lessons learned, and opportunities, including expanded genomic testing capacity, localized bioinformatics infrastructure, and reinforcement of surveillance systems. Through use-case studies on COVID-19, HIV/AIDS, malaria, Ebola, Mpox, rotavirus, and cholera, we demonstrate the impact of genomics on improving diagnostic accuracy, disease monitoring and outbreak response, identifying drug resistance, and informing targeted public health interventions. Despite these successes, challenges, including but not limited to infrastructure gaps, funding constraints, and ethical considerations, remain, underscoring the need for policy, regulation, and capacity enhancement as well as global collaboration to effectively address these obstacles. Lessons learned from these efforts provide valuable recommendations for optimizing and sustaining genomic programs in low-resource settings. By leveraging genomics, Uganda can further strengthen its ability to detect, monitor, and respond to emerging and re-emerging health threats, ultimately enhancing disease control measures and public health resilience.

  • Open Access

    Targeted Metagenomics Reveals Hidden Chickenpox Epidemic Amid Mpox Surveillance in Uganda

    by Stephen Kanyerezi, Alisen Ayitewala, Jupiter Marina Kabahita, Hellen Rosette Oundo, Julius Seruyange, Wilson Tenywa, Godwin Tusabe, Stacy Were, Moses Murungi, Martha Nabukyu, et al.

    In regions where both Mpox virus (MPXV) and varicella zoster virus (VZV) are co-circulating, overlapping clinical manifestations can complicate clinical diagnosis. During the MPXV outbreak declared in Uganda on July, 2024, symptomatic suspected cases tested PCR negative for Mpox. To determine the cause of symptoms, we employed metagenomic sequencing with a targeted Viral Surveillance panel in 284 Mpox negative samples. VZV was identified as the predominant pathogen in 86% of MPXV-negative cases, suggesting a concurrent chickenpox surge. Using the VaricellaGen pipeline for variant calling, clade typing, and phylogeny, 118 (42%) samples that achieved ≥70% genome coverage were of clade 5 based on the single-nucleotide polymorphism (SNP) dataset. This data confirms co-circulation of chickenpox during the Mpox outbreak in Uganda. Our results underscore the need for laboratory confirmation of Mpox and the inclusion of VZV in the testing algorithm during the Mpox outbreak.

  • Open Access

    HIV-DRIVES: HIV drug resistance identification, variant evaluation, and surveillance pipeline

    by Stephen Kanyerezi, Ivan Sserwadda, Aloysious Ssemaganda, Julius Seruyange, Alisen Ayitewala, Hellen Rosette Oundo, Wilson Tenywa, Brian A. Kagurusi, Godwin Tusabe, Stacy Were, et al.

    The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated, while ensuring data security and privacy for patient information. To address these challenges, here we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short reads, FASTA, and Sanger ab1.seq files.


  • Open Access

    HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline

    by Stephen Kanyerezi, Ivan Sserwadda, Aloysius Ssemaganda, Julius Seruyange, Alisen Ayitewala, Hellen Rosette Oundo, Wilson Tenywa, Brian A. Kagurusi, Godwin Tusabe, Stacy Were, et al.

    The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.

  • Open Access

    HIV-DRIVES: HIV Drug Resistance Identification, Variant Evaluation, & Surveillance Pipeline

    by Stephen Kanyerezi, Ivan Sserwadda, Aloysius Ssemaganda, Julius Seruyange, Alisen Ayitewala, Hellen Rosette Oundo, Wilson Tenywa, Brian A. Kagurusi, Godwin Tusabe, Stacy Were, et al.

    The global prevalence of resistance to antiviral drugs combined with antiretroviral therapy (cART) emphasizes the need for continuous monitoring to better understand the dynamics of drug-resistant mutations to guide treatment optimization and patient management as well as check the spread of resistant viral strains. We have recently, integrated next-generation sequencing (NGS) into routine HIV drug resistance (HIVDR) monitoring, with key challenges in the bioinformatic analysis and interpretation of the complex data generated while ensuring data security and privacy of patient information. To address these challenges, here, we present HIV-DRIVES (HIV Drug Resistance Identification, Variant Evaluation, and Surveillance), an NGS-HIVDR bioinformatics pipeline that has been developed and validated using Illumina short-reads, FASTA, and Sanger ab1.seq files.